Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Ltd. announced a proposed issue of 164,300,000 ordinary fully paid securities, scheduled for issuance on May 26, 2025. This strategic move is expected to enhance the company’s capital structure, potentially strengthening its position in the biotechnology sector and providing additional resources for its ongoing research and development efforts.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is dedicated to advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies to address unmet medical needs in oncology.
Technical Sentiment Signal: Sell
Current Market Cap: A$14.81M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.